首页|ARHGDIB在恶性肿瘤中的研究进展

ARHGDIB在恶性肿瘤中的研究进展

Research progress of ARHGDIB in malignant tumors

扫码查看
侵袭和转移是恶性肿瘤难以治疗的重要因素,ARHGDIB参与多种恶性肿瘤的侵袭和转移,是一类具有重要作用的转移抑制剂.本文阐述ARHGDIB通过调节RhoGTP酶参与多种信号通路,调控恶性肿瘤的侵袭和转移.ARHGDIB在膀胱癌、胃癌及白血病中主要通过Rac通路发挥作用,而在肺癌、肝癌和胰腺导管腺癌中,其对PI3K/PKB/Akt信号通路的调控较常见.ARHGDIB通过调控肿瘤微环境中的炎症反应抑制恶性肿瘤的转移,因此,其在不同恶性肿瘤中可通过调控不同信号通路发挥作用.
Invasion and metastasis are important factors that make malignant tumors difficult to treat.ARHGDIB is involved in invasion and metastasis of various malignant tumors and is a class of important metastasis inhibitors.This article elaborates on involvement of ARHGDIB in multiple signaling pathways by regulating Rho GTPase,regulating invasion and metastasis of malignant tumors.ARHGDIB plays a role mainly through Rae pathway in bladder cancer,gastric cancer,and leukemia,while in lung cancer,liver cancer,and pancreatic ductal adenocarcinoma,its regulation of PI3K/PKB/Akt signaling pathway is more common.ARHGDIB inhibits metastasis of malignant tumors by regulating inflammatory response in tumor microenvironment.Therefore,it can play a role in different malignant tumors by regulating different signaling pathways.

ARHGDIBMalignant tumorMetastasisRho GTPase

张婧萱、乔媛、王婷婷、赵建国、宝莹娜

展开 >

内蒙古医科大学附属医院放疗科,内蒙古呼和浩特 010030

ARHGDIB 恶性肿瘤 转移 Rho GTP酶

内蒙古自治区自然科学基金项目内蒙古自治区科技计划项目内蒙古医科大学面上项目

2019MS081242019GG150YKD2021MS032

2024

中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子:1.759
ISSN:1673-7210
年,卷(期):2024.21(19)